Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer
Keiichiro Miyajima(Jikei University School of Medicine), Takahiro Kimura(Jikei University School of Medicine), Shun Sato(Jikei University School of Medicine), Shoji Kimura(Jikei University School of Medicine), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Keiji Yasue(Higashi Nagoya National Hospital), Steffi Kar Kei Yuen(Chinese University of Hong Kong), Jun Miki(Jikei University School of Medicine), Manabu Aoki(Jikei University School of Medicine), Yusuke Koike(Jikei University School of Medicine), Takafumi Yanagisawa(Jikei University School of Medicine), Kojiro Tashiro(Jikei University School of Medicine), Shunsuke Tsuzuki(Jikei University School of Medicine), Yu Imai(Jikei University School of Medicine), Kenta Miki(Jikei University School of Medicine), Hirotaka Suzuki(Jikei University School of Medicine), Hiroyuki Takahashi(Jikei University School of Medicine), Takaya Sasaki(Jikei University School of Medicine)
Cited by 4
Related Papers
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study
|The Lancet Oncology|2020|631
Extracellular vesicles as biomarkers and therapeutic targets for cancer
|American Journal of Physiology-Cell Physiology|2019|412
Circulating miRNA panels for specific and early detection in bladder cancer
|Cancer Science|2018|282